Gatehouse Park BioHub
35 Gatehouse Drive
73 articles about Entasis Therapeutics
The regulator approved Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia. The NDA was filed by Entasis Therapeutics, which Innoviva acquired in 2022.
A unanimous FDA committee vote supported the favorable risk-benefit profile of Innoviva’s sulbactam-durlobactam for hospital-acquired A. baumannii infections.
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
Entasis Therapeutics Holdings Inc. , a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the presentation of additional safety and efficacy data from the Company’s pivotal Phase 3 ATTACK trial.
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022Six abstracts selected for presentation, including three oral presentations
Entasis Therapeutics Holdings Inc. announced that six abstracts highlighting sulbactam-durlobactam have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of Entasis Therapeutics Holdings Inc.
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc.
Burlingame, CA-based Innoviva is buying all of Waltham, MA-based Entasis Therapeutics' available shares at $2.20 per share. Currently, Innoviva owns about 60% of Entasis’ outstanding shares.
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company presented data highlights from its pivotal Phase 3 ATTACK trial at the American Thoracic Society (ATS) annual conference.
Entasis Therapeutics Holdings Inc. today announced its first quarter 2022 financial results and provided a business update.
Recently, antimicrobial resistance has re-emerged in the public limelight as an increasingly severe global health problem.
Entasis Therapeutics Holdings Inc. today announced full year 2021 financial results and provided a business update.
Entasis Therapeutics Holdings Inc. today announced that its Board of Directors received a preliminary, non-binding proposal from its majority stockholder Innoviva, Inc. (“Innoviva”) to acquire all of the outstanding equity securities of Entasis that are not currently owned by Innoviva for a per share consideration of $1.80 payable in cash.
Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022.
Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update Management to host a conference call on November 4, 2021 at 8:00am ET
Entasis Therapeutics Holdings Inc. today announced financial results for the third quarter 2021 and issued a business update for the quarter and recent weeks.
10/25/2021It was yet another busy week for clinical trial news. Here’s a look.
10/20/2021More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival.
Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
Entasis Therapeutics today announced topline results from its ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacterbaumannii.
Entasis Therapeutics Holdings Inc. announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference.
Entasis Therapeutics Holdings Inc. announced today that the Company will host a virtual webinar featuring presentations by Infectious Diseases experts David van Duin, M.D., Ph.D.